CONTEXT: Although numerous studies have explored the relation of IGF-I with cancer incidence, few have investigated the association between IGF-I and cancer mortality. OBJECTIVE: This study examined the association of serum IGF-I levels with cancer mortality in older community-dwelling men. DESIGN, SETTING, AND PARTICIPANTS: We conducted a prospective, population-based study of 633 men aged 50 yr and older (mean = 73) who attended a 1988-1991 research clinic visit when blood was obtained for measurement of IGF-I. Participants were followed for vital status through July 2006. MAIN OUTCOME MEASURE: All-cancer mortality was assessed. RESULTS: Median IGF-I was 96 ng/ml. During the 18-yr follow-up, 368 deaths occurred; 74 (20%) were due to cancer. Cox regression analyses showed a significant quadratic association between IGF-I and all-cancer mortality (P = 0.039). Higher levels of IGF-I were associated with progressively higher risk of cancer death after adjusting for age, IGF-binding protein-1, adiposity, exercise, current smoking, and previous cancer. The adjusted risk of cancer death was statistically significant for IGF-I levels above 120 ng/ml, with magnitudes of effect ranging from 1.61 [95% confidence interval (CI) = 1.28-2.02] to 2.61 (95% CI = 1.46-4.64). For the 46% of men with IGF-I above 100 ng/ml, the risk of fatal cancer was 1.82 (95% CI = 1.11-2.96) compared to the risk with lower levels. CONCLUSIONS: Higher serum IGF-I in older men is associated with increased risk of cancer death, independent of age, adiposity, lifestyle, and cancer history. These results suggest caution in the use of IGF-I-enhancing therapies to slow the adverse effects of aging.
CONTEXT: Although numerous studies have explored the relation of IGF-I with cancer incidence, few have investigated the association between IGF-I and cancer mortality. OBJECTIVE: This study examined the association of serum IGF-I levels with cancer mortality in older community-dwelling men. DESIGN, SETTING, AND PARTICIPANTS: We conducted a prospective, population-based study of 633 men aged 50 yr and older (mean = 73) who attended a 1988-1991 research clinic visit when blood was obtained for measurement of IGF-I. Participants were followed for vital status through July 2006. MAIN OUTCOME MEASURE: All-cancer mortality was assessed. RESULTS: Median IGF-I was 96 ng/ml. During the 18-yr follow-up, 368 deaths occurred; 74 (20%) were due to cancer. Cox regression analyses showed a significant quadratic association between IGF-I and all-cancer mortality (P = 0.039). Higher levels of IGF-I were associated with progressively higher risk of cancer death after adjusting for age, IGF-binding protein-1, adiposity, exercise, current smoking, and previous cancer. The adjusted risk of cancer death was statistically significant for IGF-I levels above 120 ng/ml, with magnitudes of effect ranging from 1.61 [95% confidence interval (CI) = 1.28-2.02] to 2.61 (95% CI = 1.46-4.64). For the 46% of men with IGF-I above 100 ng/ml, the risk of fatal cancer was 1.82 (95% CI = 1.11-2.96) compared to the risk with lower levels. CONCLUSIONS: Higher serum IGF-I in older men is associated with increased risk of cancer death, independent of age, adiposity, lifestyle, and cancer history. These results suggest caution in the use of IGF-I-enhancing therapies to slow the adverse effects of aging.
Authors: Eva S Schernhammer; Jeff M Holly; David J Hunter; Michael N Pollak; Susan E Hankinson Journal: Endocr Relat Cancer Date: 2006-06 Impact factor: 5.678
Authors: E Giovannucci; M N Pollak; E A Platz; W C Willett; M J Stampfer; N Majeed; G A Colditz; F E Speizer; S E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-04 Impact factor: 4.254
Authors: R Kaaks; P Toniolo; A Akhmedkhanov; A Lukanova; C Biessy; H Dechaud; S Rinaldi; A Zeleniuch-Jacquotte; R E Shore; E Riboli Journal: J Natl Cancer Inst Date: 2000-10-04 Impact factor: 13.506
Authors: Nele Friedrich; Robin Haring; Matthias Nauck; Jan Lüdemann; Dieter Rosskopf; Elisabeth Spilcke-Liss; Stephan B Felix; Marcus Dörr; Georg Brabant; Henry Völzke; Henri Wallaschofski Journal: J Clin Endocrinol Metab Date: 2009-02-17 Impact factor: 5.958
Authors: Stefan Lönn; Peter D Inskip; Michael N Pollak; Stephanie J Weinstein; Jarmo Virtamo; Demetrius Albanes Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-04 Impact factor: 4.254
Authors: Marcello Maggio; Chiara Cattabiani; Fulvio Lauretani; Stefania Bandinelli; Francesca De Vita; Elisabetta Dall'Aglio; Andrea Corsonello; Fabrizia Lattanzio; Giuseppe Paolisso; Luigi Ferrucci; Gian Paolo Ceda Journal: J Gerontol A Biol Sci Med Sci Date: 2013-05-13 Impact factor: 6.053
Authors: Mariam Haffa; Andreana N Holowatyj; Mario Kratz; Reka Toth; Axel Benner; Biljana Gigic; Nina Habermann; Petra Schrotz-King; Jürgen Böhm; Hermann Brenner; Martin Schneider; Alexis Ulrich; Esther Herpel; Peter Schirmacher; Beate K Straub; Johanna Nattenmüller; Hans-Ulrich Kauczor; Tengda Lin; Claudia R Ball; Cornelia M Ulrich; Hanno Glimm; Dominique Scherer Journal: J Clin Endocrinol Metab Date: 2019-11-01 Impact factor: 5.958